Hillhouse Leads USD160m Series B for Chinese Biopharma Genor
Source(s): DealStreetAsia
Hillhouse Capital led a USD160m Series B for China-based biopharmaceutical company Genor Biopharma, with participation from Temasek Holdings, Haitong Capital, Cavenham PE, and CR-CP Life Science Fund, a joint venture between China Resources Group and Thailand’s Charoen Pokphand Group. Read more